NASDAQ:PRVBProvention Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Provention Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.86 -0.55 (-4.10 %) (As of 05/29/2020 01:28 PM ET) Add Compare Share Today's Range$12.86Now: $12.86▼$13.6550-Day Range$8.39MA: $11.82▼$14.3152-Week Range$3.84Now: $12.86▼$22.82Volume16,721 shsAverage Volume415,483 shsMarket Capitalization$613.94 millionP/E RatioN/ADividend YieldN/ABeta4.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProvention Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.50, Provention Bio has a potential upside of 110.9% from its current price of $13.04.Amount of Analyst CoverageProvention Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesProvention Bio has received 127 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProvention Bio has received 122 “underperform” votes. (Add your “underperform” vote.)Community SentimentProvention Bio has received 51.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Provention Bio and other stocks. Vote “Outperform” if you believe PRVB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRVB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProvention Bio does not currently pay a dividend.Dividend GrowthProvention Bio does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Provention Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,125.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 19.60% of the stock of Provention Bio is held by insiders.Percentage Held by InstitutionsOnly 22.01% of the stock of Provention Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Provention Bio are expected to grow in the coming year, from ($1.16) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Provention Bio is -12.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Provention Bio is -12.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProvention Bio has a P/B Ratio of 8.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRVB Previous Symbol CUSIPN/A CIKN/A Webwww.proventionbio.com Phone908-336-0360Debt Debt-to-Equity RatioN/A Current Ratio11.32 Quick Ratio11.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book8.63Profitability EPS (Most Recent Fiscal Year)($1.06) Net Income$-43,280,000.00 Net MarginsN/A Return on Equity-63.64% Return on Assets-59.28%Miscellaneous Employees13 Outstanding Shares47,740,000Market Cap$613.94 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:PRVB Rates by TradingView Receive PRVB News and Ratings via Email Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter. Provention Bio (NASDAQ:PRVB) Frequently Asked Questions How has Provention Bio's stock been impacted by COVID-19 (Coronavirus)? Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRVB stock has increased by 44.7% and is now trading at $13.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Provention Bio? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Provention Bio. When is Provention Bio's next earnings date? Provention Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Provention Bio. How were Provention Bio's earnings last quarter? Provention Bio Inc (NASDAQ:PRVB) announced its earnings results on Thursday, May, 7th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. View Provention Bio's earnings history. What price target have analysts set for PRVB? 4 analysts have issued 1-year price objectives for Provention Bio's stock. Their forecasts range from $20.00 to $35.00. On average, they expect Provention Bio's stock price to reach $27.50 in the next year. This suggests a possible upside of 110.9% from the stock's current price. View analysts' price targets for Provention Bio. Has Provention Bio been receiving favorable news coverage? News stories about PRVB stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Provention Bio earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutProvention Bio. Are investors shorting Provention Bio? Provention Bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,760,000 shares, an increase of 13.1% from the April 30th total of 2,440,000 shares. Based on an average trading volume of 578,400 shares, the days-to-cover ratio is currently 4.8 days. Currently, 8.1% of the shares of the stock are short sold. View Provention Bio's Current Options Chain. Who are some of Provention Bio's key competitors? Some companies that are related to Provention Bio include Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), Pacira Biosciences (PCRX), Eidos Therapeutics (EIDX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Epizyme (EPZM) and Zymeworks (ZYME). View all competitors. What other stocks do shareholders of Provention Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Myovant Sciences (MYOV), VBI Vaccines (VBIV), NVIDIA (NVDA), Opko Health (OPK), Vaxart (VXRT) and Clovis Oncology (CLVS). Who are Provention Bio's key executives? Provention Bio's management team includes the following people: Mr. Ashleigh Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 56)Mr. Francisco Leon M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 47)Mr. Andrew T. Drechsler, Chief Financial Officer (Age 47)Dr. Eleanor L. Ramos, Chief Medical Officer & COO (Age 63)Mr. Cameron Gray Ph.D., MD & Director (Age 46) What is Provention Bio's stock symbol? Provention Bio trades on the NASDAQ under the ticker symbol "PRVB." Who are Provention Bio's major shareholders? Provention Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (6.31%), BlackRock Inc. (1.43%), Invesco Ltd. (1.06%), Geode Capital Management LLC (0.61%), Segantii Capital Management Ltd (0.60%) and EAM Global Investors LLC (0.30%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, Peter A Appel and Wayne Pisano. View institutional ownership trends for Provention Bio. Which major investors are selling Provention Bio stock? PRVB stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Baker Avenue Asset Management LP, Lido Advisors LLC, Wells Fargo & Company MN, Bailard Inc., Virtus ETF Advisers LLC, State Street Corp, and Sigma Planning Corp. View insider buying and selling activity for Provention Bio. Which major investors are buying Provention Bio stock? PRVB stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., EAM Global Investors LLC, EAM Investors LLC, Perceptive Advisors LLC, Sontag Advisory LLC, Rice Hall James & Associates LLC, Jane Street Group LLC, and Geode Capital Management LLC. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, Peter A Appel, and Wayne Pisano. View insider buying and selling activity for Provention Bio. How do I buy shares of Provention Bio? Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Provention Bio's stock price today? One share of PRVB stock can currently be purchased for approximately $13.04. How big of a company is Provention Bio? Provention Bio has a market capitalization of $622.53 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 13 workers across the globe. What is Provention Bio's official website? The official website for Provention Bio is www.proventionbio.com. How can I contact Provention Bio? Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
